AbbVie Cash on Hand 2010-2025 | ABBV
AbbVie cash on hand from 2010 to 2025. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
- AbbVie cash on hand for the quarter ending March 31, 2025 was $5.555B, a 56.66% decline year-over-year.
- AbbVie cash on hand for 2024 was $5.555B, a 56.66% decline from 2023.
- AbbVie cash on hand for 2023 was $12.816B, a 38.87% increase from 2022.
- AbbVie cash on hand for 2022 was $9.229B, a 6.11% decline from 2021.
AbbVie Annual Cash on Hand
(Millions of US $) |
| 2024 |
$5,555 |
| 2023 |
$12,816 |
| 2022 |
$9,229 |
| 2021 |
$9,830 |
| 2020 |
$8,479 |
| 2019 |
$39,924 |
| 2018 |
$8,061 |
| 2017 |
$9,789 |
| 2016 |
$6,423 |
| 2015 |
$8,407 |
| 2014 |
$8,374 |
| 2013 |
$9,895 |
| 2012 |
$7,976 |
| 2011 |
$653 |
| 2010 |
$11 |
| 2009 |
$0 |
AbbVie Quarterly Cash on Hand
(Millions of US $) |
| 2024-12-31 |
$5,555 |
| 2024-09-30 |
$7,285 |
| 2024-06-30 |
$13,157 |
| 2024-03-31 |
$18,069 |
| 2023-12-31 |
$12,816 |
| 2023-09-30 |
$13,290 |
| 2023-06-30 |
$8,766 |
| 2023-03-31 |
$6,722 |
| 2022-12-31 |
$9,229 |
| 2022-09-30 |
$11,879 |
| 2022-06-30 |
$9,961 |
| 2022-03-31 |
$7,572 |
| 2021-12-31 |
$9,830 |
| 2021-09-30 |
$12,249 |
| 2021-06-30 |
$8,600 |
| 2021-03-31 |
$9,777 |
| 2020-12-31 |
$8,479 |
| 2020-09-30 |
$7,950 |
| 2020-06-30 |
$6,040 |
| 2020-03-31 |
$41,142 |
| 2019-12-31 |
$39,924 |
| 2019-09-30 |
$10,648 |
| 2019-06-30 |
$5,416 |
| 2019-03-31 |
$5,228 |
| 2018-12-31 |
$8,061 |
| 2018-09-30 |
$8,785 |
| 2018-06-30 |
$3,743 |
| 2018-03-31 |
$9,474 |
| 2017-12-31 |
$9,789 |
| 2017-09-30 |
$9,554 |
| 2017-06-30 |
$7,205 |
| 2017-03-31 |
$6,248 |
| 2016-12-31 |
$6,423 |
| 2016-09-30 |
$7,950 |
| 2016-06-30 |
$8,002 |
| 2016-03-31 |
$8,600 |
| 2015-12-31 |
$8,407 |
| 2015-09-30 |
$9,249 |
| 2015-06-30 |
$8,279 |
| 2015-03-31 |
$7,924 |
| 2014-12-31 |
$8,374 |
| 2014-09-30 |
$10,323 |
| 2014-06-30 |
$10,246 |
| 2014-03-31 |
$9,100 |
| 2013-12-31 |
$9,895 |
| 2013-09-30 |
$9,596 |
| 2013-06-30 |
$8,754 |
| 2013-03-31 |
$7,479 |
| 2012-12-31 |
$7,976 |
| 2012-09-30 |
$4,586 |
| 2012-06-30 |
$75 |
| 2012-03-31 |
$43 |
| 2011-12-31 |
$653 |
| 2011-09-30 |
|
| 2011-06-30 |
|
| 2011-03-31 |
|
| 2010-12-31 |
$11 |
| 2009-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$325.053B |
$56.334B |
|
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
|
